This postdoctoral program in clinical pharmacology provides training in basic and applied human pharmacology for those committed to a career integrating basic and translational research and patient care as physician-scientists. The objective of this program is to provide training in the continuum spanning mechanistic, translational, and human clinical investigation, with an emphasis on pharmacology and experimental therapeutics, to replenish the dwindling national supply of clinician-investigators. While the majority of fellows' time is focused on research, the program also emphasizes a curriculum which forms the core of the institutional NIH K30 Training Program in Human investigation, including: courses in basic and clinical pharmacology, experimental design, statistics, epidemiology, and research ethics; conferences including journal club, case conference, research seminars, and Seminars in Clinical Pharmacology; clerkships on the Institutional Review Board, the Pharmacy and Therapeutics Committee, the editorial board of the Annals of Internal Medicine, and in pharmaceutical drug development at Merck Research Laboratories; the design and conduct of human clinical trials in the Jefferson Clinical Research Unit presentation of research results at national meetings; and the clinical pharmacology consult service. ? ? Research opportunities are offered by 28 preceptors, representing 8 departments including 5 divisions within the Department of Medicine. These preceptors represent a breadth of research disciplines, approaches and methodologies to ensure a wide selection of training opportunities for fellows. Preceptors are selected on the basis of their productive research programs in basic or translational pharmacology funded through extramural mechanisms, success in training competitive investigators, and commitment and ability to train postdoctoral fellows. Programs of these preceptors constitute 11 general areas within which there are research interactions including: Cancer Biology; Clinical Trial Design; Dermatopharmacology; Molecular Pharmacology of Signal Transduction; Gastrointestinal Pharmacology; General Clinical Pharmacology; Health Policy and Outcomes Research; Neuroscience, Cardiovascular Medicine Immunology, and Translational Medicine. ? ? Trainees are selected from candidates with M.D. or M.D./Ph.D. degrees and sufficient clinical training for primary specialty certification. In selected instances, those with Ph.D. or Pharm.D. degrees in areas related to the objectives of the program may be selected. Candidates are selected by an Advisory Committee, which monitors trainees' progress and programmatic directions. Trainees spend 2-3 years in the program; those with limited research experience spend 3 years. It is expected that at the completion of the program, trainees will seek academic appointments in clinical pharmacology or related divisions and establish research programs funded by extramural mechanisms. Alternatively, fellows may opt for careers in the pharmaceutical industry or in regulatory clinical pharmacology. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM008562-11
Application #
6845515
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PD))
Program Officer
Okita, Richard T
Project Start
1995-07-01
Project End
2010-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
11
Fiscal Year
2005
Total Cost
$226,454
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Tran, Benjamin Duy; Moorthy, Ganesh S; Zuppa, Athena F (2018) Ketamine and norketamine stability in whole blood at ambient and 4°C conditions. Biomed Chromatogr 32:
Moore, Jason N; Gastonguay, Marc R; Ng, Chee M et al. (2018) The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther 103:1029-1037
Li, Peng; Lin, Jieru E; Snook, Adam E et al. (2017) ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice. Toxins (Basel) 9:
Zane, Nicole R; Reedy, Michael D; Gastonguay, Marc R et al. (2017) A Population Pharmacokinetic Analysis to Study the Effect of Therapeutic Hypothermia on Vancomycin Disposition in Children Resuscitated From Cardiac Arrest. Pediatr Crit Care Med 18:e290-e297
Weinberg, David S; Lin, Jieru E; Foster, Nathan R et al. (2017) Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prev Res (Phila) 10:345-354
Healy, Jason R; Bezawada, Padmavani; Griggs, Nicholas W et al. (2017) Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands. Bioorg Med Chem Lett 27:666-669
Avant, Debbie; Baer, Gerri; Moore, Jason et al. (2017) Neonatal Safety Information Reported to the FDA During Drug Development Studies. Ther Innov Regul Sci 2017:1-9
Mantravadi, Santhi; Ogdie, Alexis; Kraft, Walter K (2017) Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol 10:899-910
Li, Peng; Wuthrick, Evan; Rappaport, Jeff A et al. (2017) GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Res 77:5095-5106
Moore, J N; Healy, J R; Thoma, B N et al. (2016) A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy. CPT Pharmacometrics Syst Pharmacol 5:495-502

Showing the most recent 10 out of 75 publications